CA
ONC

Continuum Advisory’s BeOne Medicines Ltd ONC Stock Holding History

Continuum Advisory’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56K Buy
+9
New +$2.65K ﹤0.01% 1667
2025
Q1 		– Sell
-6
Closed -$1.11K – 1970
2024
Q4 		$1.11K Hold
6
– – ﹤0.01% 1594
2024
Q3 		$1.16K Buy
+6
New +$1.08K ﹤0.01% 1593

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Continuum Advisory's ONC Position: Q2 2026 in Review

Continuum Advisory opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 9 shares worth $2.56K. The stake represents ﹤0.01% of the portfolio and ranks #1667 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in ONC as recently as Q4 2024.

Continuum Advisory first reported a position in ONC in Q3 2024 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Continuum Advisory held 9 shares of BeOne Medicines Ltd worth $2.56K as of Q2 2026.
  • BeOne Medicines Ltd was a new Continuum Advisory position in Q2 2026.
  • BeOne Medicines Ltd made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1667 holding.
  • Continuum Advisory first reported a position in BeOne Medicines Ltd in Q3 2024 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.